Rationale and design of a double-blind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous beta-blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention: EARLY beta-blocker Administration before primary PCI in patients with ST-elevation Myocardial Infarction trial

Vincent Roolvink*, Saman Rasoul, Jan Paul Ottervanger, Jan-Henk E. Dambrink, Erik Lipsic, Iwan C. C. van der Horst, Bart de Smet, Elvin Kedhi, A. T. Marcel Gosselink, Jan J. Piek, Vicente Sanchez-Brunete, Borja Ibanez, Valentin Fuster, Arnoud W. J. van't Hof, EARLY-BAMI Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)

Abstract

Background beta-Blockers have a class 1a recommendation in the treatment of patients with ST-elevation myocardial infarctions (STEMIs), as they are associated with a reduced mortality, recurrent myocardial infarction, life-threatening arrhythmias, and with prevention of unfavorable left ventricular remodeling. Whether early administration before primary percutaneous coronary intervention (PCI) of intravenous beta-blockers reduces the infarct size in the current era is unknown.

Hypothesis We postulate that the early administration of beta-blockers will reduce the myocardial infarcted area as assessed by magnetic resonance imaging (MRI) at 30 days.

Design In a multinational, multicenter, double-blind, placebo-controlled, randomized trial, patients with symptoms and signs of STEMI and transferred to a hospital for primary PCI will be randomized in a 1:1 fashion to intravenous metoprolol (5 mg twice daily) administration or placebo. Before admission, study treatment will be started as soon as possible after the diagnosis of STEMI. After admission, primary PCI will be performed as per standard of care. After primary PCI, medical treatment will occur as per current guidelines in all patients, including the use of oral beta-blockers. The primary end point is the myocardial infarct size as assessed by MRI at 30 days. Based on a superiority design and assuming an 18% relative infarct size reduction (from 28% to 23.5%), 408 patients are required to be enrolled, accounting for 20% drop-out (alpha =.05 and power = 80%).

Summary The EARLY-BAMI trial is a multinational, multicenter, double-blind, placebo-controlled, randomized clinical trial that will investigate the impact of intravenous metoprolol administration before primary PCI for STEMI on myocardial infarct size as measured with MRI at 30 days.

Original languageEnglish
Pages (from-to)661-666
Number of pages6
JournalAmerican Heart Journal
Volume168
Issue number5
DOIs
Publication statusPublished - Nov-2014

Keywords

  • CARDIAC MAGNETIC-RESONANCE
  • ADRENERGIC-BLOCKADE
  • EARLY METOPROLOL
  • SIZE
  • FAILURE
  • PROPRANOLOL
  • REDUCTION
  • CARDIOPROTECTION
  • CARVEDILOL
  • EFFICACY

Cite this